Anticoagulation therapy in pulmonary arterial hypertension

Satoshi Akagi, Kengo Fukushima Kusano

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Vascular thrombosis implicates in the pathogenesis of pulmonary arterial hypertension (PAH). Anticoagulation therapy (warfarin) has been recommended by many experts in the treatment of PAH. However, the long-term effectiveness of anticoagulation therapy remains controversial. Because of the various drugs, such as epoprostenol, bosentan, and sildenafil, for the treatment of PAH recently, warfarin alone is not a realistic therapy for PAH. Accordingly we reviewed the previous manuscript regarding anticoagulation therapy for PAH, and looked at the current role of anticoagulation therapy in Japan.

Original languageEnglish
Pages (from-to)2174-2178
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume66
Issue number11
Publication statusPublished - Nov 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anticoagulation therapy in pulmonary arterial hypertension'. Together they form a unique fingerprint.

  • Cite this